JP2021528384A5 - - Google Patents

Info

Publication number
JP2021528384A5
JP2021528384A5 JP2020567941A JP2020567941A JP2021528384A5 JP 2021528384 A5 JP2021528384 A5 JP 2021528384A5 JP 2020567941 A JP2020567941 A JP 2020567941A JP 2020567941 A JP2020567941 A JP 2020567941A JP 2021528384 A5 JP2021528384 A5 JP 2021528384A5
Authority
JP
Japan
Prior art keywords
acylated
item
active agent
acid
preketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528384A (ja
JP7377220B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035680 external-priority patent/WO2019236775A1/en
Publication of JP2021528384A publication Critical patent/JP2021528384A/ja
Publication of JP2021528384A5 publication Critical patent/JP2021528384A5/ja
Priority to JP2023184635A priority Critical patent/JP7592140B2/ja
Application granted granted Critical
Publication of JP7377220B2 publication Critical patent/JP7377220B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567941A 2018-06-05 2019-06-05 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法 Active JP7377220B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023184635A JP7592140B2 (ja) 2018-06-05 2023-10-27 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862680977P 2018-06-05 2018-06-05
US201862680976P 2018-06-05 2018-06-05
US62/680,976 2018-06-05
US62/680,977 2018-06-05
US201862776455P 2018-12-06 2018-12-06
US201862776448P 2018-12-06 2018-12-06
US62/776,455 2018-12-06
US62/776,448 2018-12-06
US201962828958P 2019-04-03 2019-04-03
US62/828,958 2019-04-03
PCT/US2019/035680 WO2019236775A1 (en) 2018-06-05 2019-06-05 Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023184635A Division JP7592140B2 (ja) 2018-06-05 2023-10-27 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法

Publications (3)

Publication Number Publication Date
JP2021528384A JP2021528384A (ja) 2021-10-21
JP2021528384A5 true JP2021528384A5 (https=) 2022-06-13
JP7377220B2 JP7377220B2 (ja) 2023-11-09

Family

ID=68769573

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567941A Active JP7377220B2 (ja) 2018-06-05 2019-06-05 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法
JP2023184635A Active JP7592140B2 (ja) 2018-06-05 2023-10-27 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023184635A Active JP7592140B2 (ja) 2018-06-05 2023-10-27 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法

Country Status (13)

Country Link
US (3) US10953027B2 (https=)
EP (1) EP3801496A4 (https=)
JP (2) JP7377220B2 (https=)
KR (1) KR20210016407A (https=)
CN (1) CN112367987A (https=)
AU (1) AU2019282691A1 (https=)
BR (1) BR112020024695A2 (https=)
CA (1) CA3102404A1 (https=)
IL (1) IL279161A (https=)
MX (1) MX2020013104A (https=)
PH (1) PH12020552060A1 (https=)
SG (1) SG11202011698VA (https=)
WO (1) WO2019236775A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801489A4 (en) 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. ACYLATED DRUGS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CA3102404A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
JP2021535092A (ja) 2018-08-13 2021-12-16 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 結合体およびその使用方法
CA3163342A1 (en) * 2019-12-05 2021-06-10 Flagship Pioneering Innovations V, Inc. Acylated active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
JP7737231B2 (ja) * 2020-03-31 2025-09-10 大阪瓦斯株式会社 ジオール化合物およびその重合体ならびにそれらの製造方法
WO2021222702A1 (en) * 2020-05-01 2021-11-04 Flagship Pioneering Innovations V, Inc. Crystalline forms, compositions containing them, and methods of their use
RU2742414C1 (ru) * 2020-06-16 2021-02-05 Владимир Сергеевич Понамарёв Препарат комплексный с гепатопротекторной активностью для крупного рогатого скота
JP2023532286A (ja) * 2020-06-26 2023-07-27 デュレクト コーポレーション 炎症状態を処置するための酸素化コレステロールスルフェート類の使用
WO2022140580A1 (en) * 2020-12-24 2022-06-30 Orn Almarsson Xanthophyll derivatives
JP2024502909A (ja) * 2020-12-24 2024-01-23 アルマルソン、オーン キサントフィル誘導体
CN113244208B (zh) * 2021-05-20 2022-07-12 云南中医药大学 Hpa在制备治疗非酒精性脂肪性肝病药物中的应用
WO2023280750A1 (en) * 2021-07-09 2023-01-12 Dsm Ip Assets B.V. Synthesis of butyrate compounds
JP7401156B1 (ja) 2022-11-08 2023-12-19 ミヤリサン製薬株式会社 子宮、卵管および卵巣における炎症の予防および／または治療剤
AU2023375510A1 (en) * 2022-11-10 2025-05-29 Temple University-Of The Commonwealth System Of Higher Education Methods of treating or preventing liver diseases or disorders
US20240358673A1 (en) * 2023-04-26 2024-10-31 Franco Cavaleri Short chain fatty acids & gallates compositions
CN118580213B (zh) * 2024-08-05 2024-10-11 中国农业大学 一种黄酮衍生物及其在制备治疗糖尿病药物中的用途
CN118834192A (zh) * 2024-08-20 2024-10-25 江南大学 一种4'-羟基-3, 5, 7, 3', 5'-五甲氧基黄酮、其酶法生物合成、分离制备方法及降脂活性提升研究

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO87311B (ro) * 1983-10-04 1985-12-01 Nicolaie Oita Medicament cu actiune metabolica complexa si procedeu de obtinere a acestuia
JPS6081127A (ja) 1983-10-13 1985-05-09 Chugai Pharmaceut Co Ltd 食欲抑制剤
US5385938B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
JP3165279B2 (ja) * 1993-03-29 2001-05-14 三井農林株式会社 ３−アシル化カテキンを含有する油溶性抗酸化剤
CA2283642C (en) * 1997-03-17 2012-05-15 Btg International Limited Therapeutic compositions
JPH11199598A (ja) 1998-01-08 1999-07-27 Yokohama Kokusai Bio Kenkyusho:Kk ウルソデオキシコール酸誘導体とその製造法
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
WO2001017528A1 (en) 1999-09-08 2001-03-15 Nitromed, Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
JP2002145875A (ja) 2000-11-06 2002-05-22 Fancl Corp キサンチンオキシダーゼ阻害剤
US20040033480A1 (en) 2002-08-15 2004-02-19 Wong Norman C.W. Use of resveratrol to regulate expression of apolipoprotein A1
WO2004105779A2 (en) 2003-05-27 2004-12-09 Cesare Montecucco Green tea and oplyphenol inhibitors of bacterial proteases
DE10335725A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate
US20070082944A1 (en) 2003-09-12 2007-04-12 Robert Fish Antimicrobial compositions and methods of use
KR100592796B1 (ko) * 2004-03-19 2006-06-26 삼아약품 주식회사 녹차카테킨을 유효성분으로 포함하는 고지혈증 예방 및치료제
JP4874236B2 (ja) 2004-04-26 2012-02-15 ディーエスエム アイピー アセッツ ビー．ブイ． トコフェリルアシレートの製造方法
WO2006004110A1 (ja) * 2004-07-05 2006-01-12 Suntory Limited リパーゼ阻害剤
GB0415181D0 (en) 2004-07-06 2004-08-11 School Of Pharmacy The Univers Compounds for use in the treatment of infection
US7544816B2 (en) 2004-08-19 2009-06-09 The Hong Kong Polytechnic University (−)-Epigallocatechin gallate derivatives for inhibiting proteasome
GB0425658D0 (en) 2004-11-22 2004-12-22 Stanford Rook Ltd Immunotherapeutic agent
CA2491763A1 (en) * 2005-01-06 2006-07-06 Tassos P. Anastassiades Blood glucose control with n-acylated glucosamines
JP2006249056A (ja) * 2005-03-07 2006-09-21 Mitsui Norin Co Ltd 子宮癌抑制剤
CA2606427A1 (en) 2005-04-26 2006-11-02 University Of South Florida Green tea polyphenol alpha secretase enhancers and methods of use
WO2007006308A1 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
US8076484B2 (en) 2005-08-11 2011-12-13 Georgia Health Science University Research Institute, Inc. Modified green tea polyphenol formulations
MX2009004337A (es) * 2006-11-01 2009-05-22 Pronova Biopharma Norge As Compuestos lipidos omega-3.
CN105152983A (zh) * 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
US8026285B2 (en) 2007-09-04 2011-09-27 Bezwada Biomedical, Llc Control release of biologically active compounds from multi-armed oligomers
FR2923717B1 (fr) 2007-11-15 2015-01-16 Caudalie Compositions de derives polyphenoliques stilbeniques et leurs applications pour lutter contre les pathologies et le veillissement des organismes vivants
DK2240017T3 (da) * 2008-01-04 2019-06-17 Univ Oxford Innovation Ltd Ketonlegemer og ketonlegemsestere som blodlipid-sænkende midler
ITRM20080214A1 (it) 2008-04-21 2009-10-22 Uni Degli Studi Di Napoli Federico Ii Derivati dell'acido butirrico somministrabili per via orale, formulazioni che li contengono e loro uso clinico.
KR100918776B1 (ko) * 2009-04-20 2009-09-24 계명대학교 산학협력단 폴리에틸렌 글리콜과 갈레이트 카테킨을 이용한 혈당상승 억제 조성물
ES2343773B1 (es) 2008-11-07 2011-06-24 Consejo Superior De Investigaciones Cientificas (Csic) Procedimiento enzimatico para la acilacion en posicion 3- del resveratrol.
WO2011028689A1 (en) 2009-09-01 2011-03-10 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
US9018248B2 (en) * 2010-04-08 2015-04-28 Genesis Group Inc. Fatty acid derivatives of catechins and methods of their use
KR101212612B1 (ko) * 2010-10-12 2012-12-14 전남대학교산학협력단 항산화활성 및 과산화물생성억제활성 중 하나 이상의 활성을 갖는 신규 화합물 및 퉁퉁마디로부터의 상기 신규 화합물 분리방법
CN104024213A (zh) * 2011-06-16 2014-09-03 香港理工大学 合成的表没食子儿茶素没食子酸酯(egcg)类似物
CN103987704A (zh) * 2011-08-05 2014-08-13 卡德尔治疗公司 类黄酮化合物
WO2013115742A1 (en) * 2012-01-31 2013-08-08 Mahmut Bilgic Pharmaceutical composition comprising alpha-glucosidase inhibitor
SK50062012A3 (sk) 2012-02-29 2013-09-03 Ustav Experimentalnej Farmakologie A Toxikologie Sav Quercetin derivatives, pharmaceutical compositions comprising them and their use
CA3291904A1 (en) 2012-06-27 2026-03-02 Amazentis Sa Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
HK1210971A1 (en) 2012-08-20 2016-05-13 The Hong Kong Polytechnic University Prodrug of green tea epigallocatechin-3-gallate (pro-egcg) for use in the treatment of endometriosis
KR101480600B1 (ko) * 2013-01-22 2015-01-08 경북대학교 산학협력단 레스베라트롤 유도체의 피부미백 용도
CN112724114A (zh) 2013-04-04 2021-04-30 斯法尔制药私人有限公司 表儿茶素及相关多酚
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
WO2015019193A2 (en) 2013-08-08 2015-02-12 Dalhousie University Acylated derivatives of phloridzin and isoquercetrin as anticancer therapeutics and methods of use thereof
US20150056194A1 (en) * 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Modified green tea polyphenols and methods thereof for treating liver disease
KR101963946B1 (ko) * 2014-05-20 2019-03-29 아스타 파마슈티칼즈 가부시키가이샤 카로테노이드 유도체, 그 약학상 허용되는 염 또는 그 약학상 허용되는 에스테르류 혹은 아미드류
WO2016013654A1 (ja) 2014-07-24 2016-01-28 株式会社プロテクティア アレルゲン活性の抑制剤およびその用途
EP3180023B1 (en) 2014-08-13 2020-02-19 The Regents of The University of California Biodegradable trehalose glycopolymers
CN107427489A (zh) * 2014-08-22 2017-12-01 财团法人教育研究基金会 用于治疗非酒精性脂肪肝疾病的药物及应用
WO2016086453A1 (zh) * 2014-12-04 2016-06-09 中国药科大学 五环三萜类胆固醇酯转运蛋白抑制剂、其药物组合物及医药用途
KR101702076B1 (ko) 2015-02-25 2017-02-02 주식회사 휴메딕스 지방산 컨쥬게이션된 7-데하이드로콜레스테롤 유도체
CN104940181B (zh) * 2015-06-29 2018-02-16 齐锦生 β‑羟丁酸或其药学上可接受的盐的用途
US9545419B1 (en) * 2015-11-24 2017-01-17 Elorac Inc Method and compositions for treating chronic inflammatory disorders
AU2016383376B2 (en) * 2015-12-31 2022-07-28 Beijing Gushen Life Health Technology Co., Ltd. Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
JP6830580B2 (ja) 2016-01-13 2021-02-17 国立大学法人富山大学 セラミド含量増加剤
WO2017132775A1 (en) 2016-02-05 2017-08-10 Viteava Pharmaceuticals Inc. Novel compositions and methods for the treatment of leiomyoma
CN106995474B (zh) * 2017-04-25 2019-11-05 中国海洋大学 双半乳糖基二酰基甘油酯及其制备方法与用途
JP2020522514A (ja) 2017-06-05 2020-07-30 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド マルチバイオティック剤及びその使用方法
EP3801489A4 (en) * 2018-06-05 2022-03-30 Flagship Pioneering Innovations V, Inc. ACYLATED DRUGS AND METHODS OF USE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CA3102404A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease
WO2019236765A1 (en) 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Acylated catechin polyphenols and methods of their use for the treatment of cancer
JP2021535092A (ja) 2018-08-13 2021-12-16 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド 結合体およびその使用方法
WO2021222702A1 (en) * 2020-05-01 2021-11-04 Flagship Pioneering Innovations V, Inc. Crystalline forms, compositions containing them, and methods of their use

Similar Documents

Publication Publication Date Title
JP2021528384A5 (https=)
JP6777366B2 (ja) スルホラファンとシリマリン及び／又はシリビニンを含有してなるオオアザミ抽出物または粉末を含む組成物
JP2020522514A5 (https=)
JP2018021079A5 (https=)
ES2585066T3 (es) Composiciones para el tratamiento de trastornos neurológicos
WO2009082459A2 (en) Anti-aging composition containing resveratrol and method of administration
AU2015320975A1 (en) Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
KR101380140B1 (ko) 트리아세틸-3-히드록실페닐아데노신 및 혈지조절에 대한 용도
JP2007535575A (ja) 生物活性化合物およびその使用方法
EP2730286A2 (en) Composition for maintaining bone health and for treating osteoarthritis and osteoarthrosis of the joints
Jangra et al. Ameliorative effect of fermentable fibres on adiposity and insulin resistance in C57BL/6 mice fed a high-fat and sucrose diet
JP2009007313A (ja) 筋萎縮抑制剤
WO2018102914A1 (en) Use of medium-chain triglycerides for the management of metabolic conditions
JP2017052747A (ja) ウロプラキン発現促進剤
JP2019147772A (ja) ヘプシジン発現抑制剤、並びに鉄欠乏性貧血改善及び／又は予防用飲食品
US20070066567A1 (en) Use of phospholipid arachidonic acids for increasing muscle mass in humans
KR20240141767A (ko) 미토콘드리아 질량 및 기능 증가를 촉진하기 위한 용도 및 방법
KR100771322B1 (ko) 항비만제 및 건강식품
CN104379214A (zh) 用于治疗代谢紊乱的野葛和植物甾醇
AU2019350801C1 (en) Fat accumulation inhibitor and blood lipid level improving agent
JP6018800B2 (ja) 経口投与組成物
RU2020142587A (ru) Активные средства и способы их применения для лечения метаболических нарушений и неалкогольной жировой болезни печени
JP2021535210A5 (https=)
JP2023505233A5 (https=)
JP2023504547A5 (https=)